CGEM NASDAQ
Cullinan Therapeutics, Inc.
1W: -13.4%
1M: +1.0%
3M: +2.4%
YTD: +38.1%
1Y: +77.0%
3Y: +53.1%
5Y: -49.5%
$13.84
-0.14 (-1.00%)
Weekly Expected Move ±10.4%
$12
$14
$16
$17
$19
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
3 bullish
0 neutral
0 bearish
Articles (7d)
3
Daily Sentiment (7 Days)
Articles (30)
Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress
Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress
Cullinan Therapeutics GAAP EPS of -$0.75
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
Global Business Travel Group Posts Upbeat Q1 Results, Joins Cabaletta Bio, Aura Biosciences And Other Big Stocks Moving Higher On Monday
Cullinan wins FDA review for cancer therapy developed with Taiho
JPMorgan Chase & Co. Has $189,000 Stake in Cullinan Therapeutics, Inc. $CGEM
Will Health Benefits Weakness Drag Elevance's Q1 Earnings?
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Cullinan Therapeutics GAAP EPS of -$0.77 misses by $0.05
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
AXQ Capital LP Purchases Shares of 32,669 Cullinan Therapeutics, Inc. $CGEM
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
Cullinan Therapeutics: Thesis Strengthening For This T-Cell Engager Specialist
Cullinan Therapeutics Tees Up Catalyst-Heavy 2026 With Q2 CLN-978 Data and AML Fast Track Momentum
Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026
Cullinan Therapeutics: Cash-Rich Biotech With Multiple Value Drivers
Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones
Cullinan Therapeutics (NASDAQ:CGEM) Trading 3.9% Higher – What’s Next?
Cullinan Therapeutics (NASDAQ:CGEM) versus Precision BioSciences (NASDAQ:DTIL) Critical Analysis
Assenagon Asset Management S.A. Has $1.05 Million Stake in Cullinan Therapeutics, Inc. $CGEM
Cullinan Therapeutics (NASDAQ:CGEM) Insider Jennifer Michaelson Sells 1,345 Shares
Cullinan Therapeutics (NASDAQ:CGEM) Insider Sells $28,023.66 in Stock
Cullinan Therapeutics, Inc. (CGEM) Discusses Initial CLN-049 Results and Development Strategy for AML Applications Transcript
Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting
Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations